Toxicity of rapamycin—A comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat

Transplantation

Volumn 52, Issue 2, 1991, Pages 203-208

  Whiting, P H ^a   Woo, J ^a   Adam, B J ^a   Hasan, N U ^a   Davidson, R J L ^b   Thomson, A W ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG COMBINATION; DRUG TOXICITY; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMAL; ANTIBIOTICS, ANTIFUNGAL; BLOOD GLUCOSE; BODY WEIGHT; COMPARATIVE STUDY; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC SYSTEM; IMMUNOTHERAPY; KIDNEY; LIVER; MALE; POLYENES; RATS; RATS, INBRED STRAINS; SIROLIMUS;

EID: 0025789057     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199108000-00004     Document Type: Article

References (36)

1. Todo S, Fung JJ, Demetris AJ, et al. Early trials with FK-506 as primary treatment in liver transplantation. Transplant Proc 1990; 22: 13.
2. Starzl TE, Todo S, Fung J, et al. FK-506 for liver, kidney and pancreas transplantation. Lancet 1989; 2: 1000.
3. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanism of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251.
4. Caine RY, Collier DSU, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
5. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK-506 and rapamycin on the suppression of allograft rejection. Transplant Proc 1990; 22: 1638.
6. Ochiai T, Nakajima K, Nagata M, et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK-506 in heterotopic cardiac allotransplantation in rats. Transplantation 1987; 44: 734.
7. Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK-506 on renal allografting in the beagle dog. Transplantation 1987; 44: 729.
8. Todo S, Demetris A, Ueda Y, et al. Renal transplantation in baboons under FK-506. Surgery 1989; 106; 444.
9. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces: II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256.
10. Tocci MJ, Matkovich DA, Collier KA, et al. FK-506 selectivity inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718.
11. Yoshimura N, Matsui S, Hamashima T, et al. Effect of a new immunosuppressive agent, FK-506, on human lymphocyte responses in vitro: II. Inhibition of the production of IL-2 and γ-IFN, but not B cell-stimulating factor 2. Transplantation 1989; 47: 35.
12. Dumont FJ, Melino MR, Staruch MJ, et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
13. Shapiro R, Fung JJ, Jain AB, et al. The side effects of FK-506 in humans. Transplant Proc 1990; 22 (suppl 1): 35.
14. Thomson AW. FK-506: profile of an important new immunosuppressant. Transplant Rev 1990; 4:1.
15. Blair JT, Thomson AW, Whiting PH, et al. Toxicity of the immune suppressant cyclosporin A in the rat. J Pathol 1982; 138:163.
16. Stephen M, Woo J, Hasan NU, et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat: a comparative and combination study with cyclosporine. Transplantation 1989; 47: 60.
17. Thomson AW, Whiting PH, Blair JT, et al. Pathological changes developing in the rat during a 3-week course of high-dosage cyclosporin A and their reversal following drug withdrawal. Transplantation 1981; 32: 271.
18. Ryffel B, Foxwell BM, Gee A, et al. Cyclosporine—relationship of side effects to mode of action. Transplantation 1988; 46: 90S.
19. Thomson AW, Mathie IH, Sewell HF. Cyclophosphamide-induced eosinophilia in the rat: concomitant changes in T cell subsets, B cells and large granular lymphocytes within lymphoid tissues. Immunology 1987; 60: 383.
20. Collier DStJ, Caine R, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990; 22: 1674.
21. Martell RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48.
22. Thomson AW, Whiting PH, Simpson JG. Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions 1984; 15: 306.
23. Yale JF. Effects of cyclosporine on glucose tolerance in the rat. Diabetes 1985; 34: 1309.
24. Whiting PH, Thomson KJ, Saunders NJ, et al. The effects of cyclosporin A on glucose homeostasis and the kidney in the normal rat. Br J Exp Pathol 1990; 71: 245.
25. Helmchen U, Schmidt WE, Siegel E, et al. Morphological and functional changes in pancreatic cells in cyclosporin A-treated rats. Diabetologia 1984; 27: 416.
26. Whiting PH, Thomson AW. Pathological effects of cyclosporin A in experimental models. In: Thomson AW, ed. Cyclosporin: mode of action and clinical applications. London: Kluwer Academic, 1989: 302.
27. Nalesnik MA, Todo S, Murase N, et al. Toxicology of FK-506 in the Lewis rat. Transplant Proc 1987; 19 (suppl 6); 89.
28. Ptachcinski RJ, Carpenter BJ, Burckart GJ, et al. Effect of erythromycin on cyclosporine levels. N Engl J Med 1985; 313: 1416.
29. Burke MD, Omar G, Thomson AW, et al. FK-506 inhibits cyclosporin A metabolism by human liver microsomes. Transplantation 1990; 50: 901.
30. Whiting PH, Simpson JG, Davidson RJL, et al. The toxic effects of combined administration of cyclosporin A and gentamycin. Br J Exp Pathol 1982; 63: 554.
31. Termeer A, Hoitsma AJ, Koene RA. Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporin in renal allograft recipients. Transplantation 1986; 42: 220.
32. Hourmant M, LeBigot JF, Vernillet L, et al. Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant Proc 1985; 17: 2723.
33. Beschorner WE, Namnoum JD, Hess AD, et al. Cyclosporin A and the thymus: immunopathology. Am J Pathol 1987; 126: 487.
34. Pugh-Humphreys RGP, Ross CSK, Thomson AW. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology 1990; 70: 398.
35. Thiru S, Collier DSU, Caine R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK- 506. Transplant Proc 1987; 19 (suppl 6): 98.
36. Tiebosch A, Ericzon B-G, Wijnen R, et al. Side effects of FK-506 in cynomologous monkeys: a histopathologic study. Transplant Proc 1990; 22: 1652.